Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia
详细信息 查看全文
- 作者：Julio C. Chavez<sup> ; sup><sup>julio.c.chavez@moffitt.org" class="auth_mail" title="E-mail the corresponding authorsup> ; Miguel Piris-Villaespesa ; Samir Dalia ; John Powers ; Elyce Turba ; Lisa Nodzon ; Rami Komrokji ; Lubomir Sokol ; Frederick L. Locke ; Jeffrey Lancet ; Eduardo M. Sotomayor ; Mohamed A. Kharfan-Dabaja ; Javier Pinilla-Ibarz
- 关键词：CLL ; Refractory ; Lenalidomide ; Rituximab
- 刊名：Leukemia Research
- 出版年：2016
- 出版时间：August 2016
- 年：2016
- 卷：47
- 期：Complete
- 页码：78-83
- 全文大小：814 K
文摘
- ss="listitem" id="list_lis0005">
- ss="label">•
Chronic lymphocytic leukemia (CLL) remains an incurable disease with conventional chemotherapy or chemoimmunotherapy.
- ss="label">•
Lenalidomide and rituximab is effective in heavily pretreated CLL.
- ss="label">•
Lenalidomide and rituximab has an acceptable toxicity profile in previously treated CLL.